126
Participants
Start Date
May 5, 2022
Primary Completion Date
May 18, 2023
Study Completion Date
May 18, 2023
Rimegepant
75 mg ODT
Placebo
matching placebo
North Suffolk Neurology, Commack
University of Rochester, Rochester
University of Pittsburgh, Pittsburgh
Perelman Center for Advanced Medicine, Philadelphia
Duke University, Raleigh
The Medici Medical Research, LLC, Hollywood
The Medici Medical Research, Hollywood
SouthCoast Research Center, Inc, Miami
SouthCoast Research Center, Miami
Oceane7 Medical & Research Center, Inc., Miami
Florida Craniofacial Institute, Tampa
Forcare Clinical Research, Tampa
University of Kentucky, College of Dentistry, Lexington
Kulkarni Orthodonties, Springboro
META Medical Research Institute,LLC., Dayton
Meta Medical Research, Dayton
Campus Health, Indiana University-Purdue University Indianapolis, Indianapolis
IDS-IU Simon Cancer Center (IUSCC), Indianapolis
Indiana University School of Dentistry, Indianapolis
TMD, Orofacial Pain and Dental Sleep Medicine Clinic, School of Dentistry, University of Minnesota, Minneapolis
University of Minnesota, Minneapolis
Clinvest Research, LLC, Springfield
Clinvest Research, Springfield
FMC Science, Lampasas
Red Star Research, LLC, Lake Jackson
Red Star Research, Lake Jackson
JBR Clinical Research, Salt Lake City
JBR, Salt Lake City
Bruce Nelson, DDS, Phoenix
Arizona Research Center, Phoenix
Northwest Clinical Research Center, Bellevue
Snoring and Sleep Apnea Center (DC/TMD Exam - Dr. Christian), Seattle
Lead Sponsor
Pfizer
INDUSTRY